News
-
-
PRESS RELEASE
CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory
CROSSJECT publishes its 2025 financial results, showing improved operating revenue and net loss. Strengthening operational, industrial, and financial trajectory highlighted for ZEPIZURE® and ZENEO® platform development -
-
-
-
-
-
PRESS RELEASE
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)
CROSSJECT secures $11.3 million BARDA funding for ZEPIZURE® development towards FDA authorization. Advances include validation batches and facility audit completion -
-
